
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Frontline PD‑1 plus BCG: Should Patients Receive It?
Panelists discuss CREST/POTOMAC clinical benefit versus toxicity, patient selection, and trade-offs of early PD‑1 use.
Play episode from 20:33
Transcript


